Targeting the BRCA1/2 tumor suppressors

Current Drug Targets

Volumn 15, Issue 1, 2014, Pages 17-31

  Rosen, Eliot M ^a   Pishvaian, Michael J ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

BRCA1; BRCA2; DNA repair; Homology directed repair (HDR); Mutation; Olaparib; PARP1; Synthetic lethality

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NIRAPARIB; OLAPARIB; PACLITAXEL; RAD51 PROTEIN; RUCAPARIB; TOPOTECAN; VELIPARIB; INIPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE;

APOPTOSIS; BREAST CANCER; CELL CYCLE CHECKPOINT; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; EXCISION REPAIR; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENOMIC INSTABILITY; HUMAN; MISMATCH REPAIR; NEOPLASM; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVIEW; SENSITIVITY ANALYSIS; TUMOR SUPPRESSOR GENE; ALLELE; ARTICLE; BRCA1 TUMOR SUPPRESSOR GENE; BRCA2 TUMOR SUPPRESSOR GENE; CANCER SUSCEPTIBILITY; CELL CYCLE PROGRESSION; CHROMATID; DNA DAMAGE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TARGETING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PROGRESSION FREE SURVIVAL; TUMOR CELL;

BASE PAIR MISMATCH; DNA MISMATCH REPAIR; GENE TARGETING; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; HUMANS;

EID: 84892961486     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450114666140106095432     Document Type: Review

References (177)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
3. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85: 1009-23.
4. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386: 804-10.
5. Merajver SD, Frank TS, Xu J, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995; 1: 539-44.
6. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995; 10: 1673-5.
7. Rosen EM, Fan S, Ma Y. BRCA1 regulation of transcription. Cancer Lett 2006; 236: 175-85.
8. Zhu Q, Pao GM, Huynh AM, et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011; 477: 179-84.
9. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88: 265-75.
10. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997; 90: 425-35.
11. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57: 1222-7.
12. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3: 389-95.
13. Weaver Z, Montagna C, Xu X, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002; 21: 5097-107.
14. Shen SX, Weaver Z, Xu X, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998; 17: 3115-24.
15. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999; 4: 1093-99.
16. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. PNAS USA 2001; 98: 5134-9.
17. Brandsma I, Gent DC. Pathway choice in DNA double strand break repair: observations of a balancing act. Genome Integr 2012; 3: 9.
18. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511-8.
19. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001; 61: 4842-50.
20. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005; 308: 551-4.
21. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007; 6: 931-42.
22. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001; 276: 42462-7.
23. Lou Z, Minter-Dykhouse K, Franco S, et al. MDC1 maintains genomic stability by participating in the amplification of ATMdependent DNA damage signals. Mol Cell 2006; 21: 187-200.
24. Costes SV, Chiolo I, Pluth JM, Barcellos-Hoff MH, Jakob B. Spatiotemporal characterization of ionizing radiation induced DNA damage foci and their relation to chromatin organization. Mutat Res 2010; 704: 78-87.
25. Yan J, Jetten AM. RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett 2008; 271: 179-90.
26. Sobhian B, Shao G, Lilli DR, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316: 1198-202.
27. Wang B. BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci 2012; 2: 6.
28. Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, et al. A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. Mol Cell 2013; 49: 872-83.
29. Chapman JR, Barral P, Vannier JB, et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell 2013; 49: 858-71.
30. Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ 3rd, Cowan KH. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 1996; 7: 717-23.
31. Vaughn JP, Davis PL, Jarboe MD, et al. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 1996; 7: 711-5.
32. Xu B, Kim St, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21: 3445-50.
33. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002; 62: 4588-91.
34. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333-7.
35. Yang H, Jeffrey PD, Miller J, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002; 297: 1837-48.
36. Yang H, Li Q, Fan J, Holloman WK, Pavletich NP. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNAssDNA junction. Nature 2005; 433: 653-7.
37. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-72.
38. Shivji MK, Mukund SR, Rajendra E, Chen S, Short JM, Savill J, Klenerman D, Venkitaraman AR. The BRC repeats of human BRCA2 differentially regulate RAD51 binding on single-versus double-stranded DNA to stimulate strand exchange. Proc Natl Acad Sci USA 2009; 106: 13254-9.
39. Rajendra E, Venkitaraman AR. Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase. Nucleic Acids Res 2010; 38: 82-96.
40. Esashi F, Galkin VE, Yu X, Egelman EH, West SC. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat Struct Mol Biol 2007; 14: 468-74.
41. Andersen SL, Sekelsky J. Meiotic versus Mitotic Recombination: Two Different Routes for Double-Strand Break Repair: The different functions of meiotic versus mitotic DSB repair are reflected in different pathway usage and different outcomes. Bioessays 2010 32: 1058-66.
42. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-9.
43. Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 2003; 12: 2503-10.
44. Hinz JM. Role of homologous recombination in DNA interstrand crosslink repair. Environ Mol Mutagen 2010; 51: 582-603.
45. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009; 43: 223-49.
46. Kurosaki T, Ushiro H, Mitsuuchi Y, et al. Primary structure of human poly(ADP-ribose) synthetase as deduced from cDNA sequence. J Biol Chem 1987; 262: 15990-7.
47. Alkhatib HM, Chen D, Cherney B, et al. Cloning and expression of cDNA for human poly (ADP-ribose) polymerase. Proc Natl Acad Sci USA 1987; 84: 1224-8.
48. Yu S-W, Wang H, Poitras MF, et al. Mediation of poly(ADPribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297: 259-63.
49. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL. NAD(+)-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004; 119: 803-14.
50. Andrabi SA, Kim NS, Yu S-W, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA 2006; 103: 18308-13.
51. Langelier M-F, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 2012; 336: 728-32.
52. Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 2012; 26: 417-32.
53. Beneke S. Regulation of chromatin structure by poly(ADPribosyl) ation. Front Genet 2012; 3: 169.
54. Ueda K, Oka J, Naruniya S, Miyakawa N, Hayaishi O. PolyADPriboseglycohy-drolase from rat live rnuclei, a novel enzyme degrading the polymer. Biochem Biophys Res Commun 1972; 46: 516-23.
55. Oka S, Kato J, Moss J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem 2006; 281: 705-13.
56. Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012; 30: 283-8.
57. Otto H, Reche PA, Bazan F, Dittmar K, Haag F, Koch-Nolte F. In silico characterization of the family of PARP-like poly(ADPribosyl) transferases (pARTs). BMC Genomics 2005; 6: 139.
58. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012; 84: 137-46.
59. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008; 13: 3046-82.
60. Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012; 19: 3907-21.
61. Smulson ME, Schein P, Mullins DW, Sudhakar S. A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res 1977; 37: 3006-12.
62. Benjamin RC, Gill DM. Poly(ADP-ribose) synthesis In vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks. J Biol Chem 1980; 255: 10502-8.
63. Berger NA, Sikorski GW, Petzold SJ, Kurohara, KK. Defective poly(adenosine diphosphoribose) synthesis in xeroderma pigmentosum. Biochemistry 1980; 19: 289-93.
64. Masson M, Niedergang C, Schreiber V, et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18: 3563-71.
65. Schreiber V, Amé JC, Dollé P, Schultz I, Rinaldi B, Fraulob V, Ménissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polym erase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277: 23028-36.
66. Leppard JB, Dong Z, Mackey ZB, Tomkinson AE. Physical and functional interaction between DNA ligase IIIalpha and poly(ADPRibose) polymerase 1 in DNA single-strand break repair. Mol Cell Biol 2003; 23: 5919-27.
67. Pinnola A, Naumova N, Shah M, Tulin AV. Nucleosomal core histones mediate dynamic regulation of poly(ADP-ribose) polymerase 1 protein binding to chromatin and induction of its enzymatic activity. J Biol Chem 2007; 282: 32511-59.
68. Messner S, Altmeyer M, Zhao H, et al. PARP1 ADP-ribosylates lysine residues of the core histone tails. Nucleic Acids Res 2010; 38: 6350-62.
69. Ali AA, Timinszky G, Arribas-Bosacoma R, et al. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol 2012; 19: 685-92.
70. Langelier MF, Planck JL, Roy S, Pascal JM. Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 2011; 286: 10690-20701.
71. Tao Z, Gao P, Liu HW. Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications. J Am Chem Soc 2009; 131: 14258-60.
72. Rodriguez MC, Songyang Z. BRCT domains: phosphopeptide binding and signaling modules. Front Biosci 2008; 13: 5905-15. Review.
73. Bork P, Hofmann K, Bucher P, et al. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997; 11: 68-76.
74. Kraus WL. New functions for an ancient domain. Nat Struct Mol Biol 2009; 16: 904-7.
75. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2007; 434: 913-6.
76. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24: 679-86.
77. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
78. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
79. McCabe N, Lord CJ, Tutt AN, et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4: 934-6.
80. Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics. 1968; 59: 37-44.
81. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003; 2: 955-69.
82. Strande NT, Waters CA, Ramsden DA. Resolution of complex ends by Nonhomologous end joining-better to be lucky than good? Genome Integr 2012; 3: 10.
83. Wang C, Lees-Miller SP. Detection and repair of ionizing radiation-induced DNA double strand breaks: new developments in nonhomologous end joining. Int J Radiat Oncol Biol Phys 2013; 86(3): 440-9.
84. Chernikova SB, Wells RL, Elkind MM. Wortmannin sensitizes mammalian cells to radiation by inhibiting the DNA-dependent protein kinase-mediated rejoining of double-strand breaks. Radiat Res 1999; 151: 159-66.
85. Kirchgessner CU, Patil CK, Evans JW, et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995; 267: 1178-83.
86. Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006; 25: 1305-14.
87. Saberi A, Hochegger H, Szuts D, et al. RAD18 and poly(ADPribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair. Mol Cell Biol 2007; 27: 2562-71.
88. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA 2011; 108: 3406-11.
89. Bunting SF, Callén E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141: 243-54.
90. Chapman JR, Barral P, Vannier JB, et al. RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection. Mol Cell 2013; 49: 858-71.
91. Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, et al. A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. Mol Cell 2013; 49: 872-83.
92. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADPribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010; 20: 274-81.
93. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
94. Williamson CT, Muzik H, Turhan AG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010; 9: 347-57.
95. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells In vitro and In vivo. Blood 2010; 116: 4578-87.
96. Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. Mol Pharmacol 2012; 82: 767-76.
97. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013; 73(12): 3683-91.
98. O'Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet 2006; 7: 45-54.
99. Wang H, Wang H, Powell SN, Iliakis G, Wang Y. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res 2004; 64: 7139-43.
100. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010; 70: 5457-64.
101. Minami D, Takigawa N, Takeda H, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013; 11: 140-8.
102. Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011; 8: 302-306.
103. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.
104. Hunt CR, Gupta A, Horikoshi N, Pandita TK. Does PTEN loss impair DNA double-strand break repair by homologous recombination? Clin Cancer Res 2012; 18: 920-2.
105. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A. MSH3 Mediates Sensitization of Colorectal Cancer Cells to Cisplatin, Oxaliplatin, and a Poly(ADP-ribose) Polymerase Inhibitor. J Bio Chem 2011; 286: 12157-65.
106. Vilar E, Bartnik C, Stenzel SL, et al. MRE11 deficiency increases sensitivity to Poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011; 71: 2632-42.
107. Leichman LP, Cohen SJ, Hochster HS, et al. A phase II trial to assess the single-agent efficacy and safety of the PARP inhibitor olaparib (O) in previously treated patients (pts) with metastatic, measurable colorectal cancer (mCRC) stratified by microsatellite status (MSs). ASCO-AACR Molecular Markers Meeting. 2010; Abstract 118.
108. Pishvaian MJ, Slack R, Witkiewicz A, et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. J Clin Oncol 2011; 29: (suppl; abstr 3502).
109. Griffin RJ, Curtin NJ, Newell DR, et al. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995; 77: 408-22.
110. Sugo N, Niimi N, Aratani Y, et al. Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase α-deficient mice. Biochem Biophys Res Commun 2007; 354: 656-61.
111. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31: 603-17.
112. Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol 2012; 82: 322-32.
113. Kimbung S, Biskup E, Johansson I, et al. Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Lett 2012; 319: 232-241.
114. Yi YW, Kang HJ, Kim HJ, et al. Bae I. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Mol Carcinog 2012; Apr 4. doi: 10. 1002/mc. 21905. [Epublished ahead of print].
115. Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 2011; 30: 2443-50.
116. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2: 1048-63.
117. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptoralpha activity. Mol Endocrinol 2007; 21: 1905-23.
118. Xiang T, Ohashi A, Huang Y, et al. Negative Regulation of AKT Activation by BRCA1. Cancer Res 2008; 68: 10040-4.
119. Tierney BJ, McCann GA, Cohn DE, et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther 2012; 13: 766-75.
120. Fan S, Meng Q, Auborn K, Carter T, Rosen EM. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 2006; 94: 407-26.
121. De Assis S, Warri A, Benitez C, Helferich W, Hilakivi-Clarke L. Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression. Cancer Prev Res (Phila) 2011; 4: 1436-48.
122. Cabanes A, Wang M, Olivo S, et al. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 2004; 25: 741-8.
123. Fan S, Meng Q, Saha T, Sarkar FH, Rosen EM. Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res 2009; 69: 6083-91.
124. Sgagias MK, Wagner KU, Hamik B, et al. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004; 3: 1451-6.
125. Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts In vivo. Cancer Biol Ther 2009; 8: 648-53.
126. Santarosa M, Del Col L, Tonin E, Caragnano A, Viel A, Maestro R. Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. Mol Cancer Ther 2009; 8: 844-54.
127. Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinumbased chemotherapy in breast and ovarian cancer. Epigenetics 2012; 7: 1225-9.
128. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-6.
129. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29: 3008-15.
130. Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 2013 23: 693-704.
131. Mackay J, Szecsei CM. Genetic counselling for hereditary predisposition to ovarian and breast cancer. Ann Oncol 2010; 21 (Suppl 7): vii334-8.
132. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Brit J Cancer 2007; 96: 11-5.
133. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-47.
134. Soldatenkov VA, Smulson M. Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. Int J Cancer 2000; 20: 59-67.
135. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-14.
136. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: (suppl; abstr 1007).
137. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase In vitro. Clin Cancer Res 2012; 18: 1655-62.
138. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 14: 917-21.
139. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNAdamaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-37.
140. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
141. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 24: 235-44.
142. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 24: 245-51.
143. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-92.
144. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-9.
145. Konstantinopoulos PA, Cannistra SA. Comparing poly (ADPribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J Clin Oncol 2012; 30: 347-50.
146. Khan OA, Gore M, Lorigan P, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011; 104: 750-5.
147. Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106: 468-74.
148. Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 2012; 30: 1493-500.
149. Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18: 2344-51.
150. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27: 2705-11.
151. Hussain M, Carducci MA, Slovin SF, et al. Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012; (suppl 5; abstr 224).
152. Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011; 71: 5626-34.
153. Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012; 18: 1726-34.
154. Somlo G, Frankel PH, Luu TH, et al. Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCAassociated breast cancer. J Clin Oncol 2013; 31 (suppl; abstr 1024).
155. Bell-McGuinn KM, Gray HJ, Fleming GF, et al. Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors. J Clin Oncol 2013; 31: (suppl; abstr 2584).
156. Appleman LJ, Beumer JH, Jiang Y, et al. A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies. J Clin Oncol 2012; 30: (suppl; abstr 3049).
157. Tan AR, Toppmeyer D, Stein MN, et al. Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. J Clin Oncol 2011; 29: (suppl; abstr 3041).
158. Pishvaian MJ, Wang H, Zhuang T, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 2012; 30: (suppl 34; abstr 147).
159. LoRusso P, Ji J, Li J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADPribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29: (suppl; abstr 3000).
160. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-23.
161. Plummer R, Lorigan P, Steven N, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013; 71: 1191-9.
162. Kristeleit RS, Shapiro G, LoRusso P, et al. A phase I doseescalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. J Clin Oncol 2013; 31: (suppl; abstr 2585).
163. Molife LR, Roxburgh P, Wilson RH, et al. A phase I study of oral rucaparib in combination with carboplatin. J Clin Oncol 2013; 31: (suppl; abstr 2586).
164. Campone M, Plummer R, Stephens P, et al. Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595). J Clin Oncol 2012; 30: (suppl; abstr 3052).
165. Schelman WR, Sandhu SK, Garcia VM, et al. First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCAdeficient tumors and sporadic ovarian cancers (soc). J Clin Oncol 2011; 29: (suppl; abstr 3102).
166. Russo AL, Kwon HC, Burgan WE, et al. In vitro and In vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 15: 607-12.
167. van Vuurden DG, Hulleman E, Meijer OL, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011; 2: 984-96.
168. Kleinberg L, Supko JG, Mikkelsen T, et al. Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data. J Clin Oncol 2013; 31: (suppl; abstr 2065).
169. Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair (Amst) 2013; 12: 394-402.
170. Daemen A, Wolf DM, Korkola JE, et al. Cross-platform pathwaybased analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 2012; 135: 505-17.
171. Liu X, Han EK, Anderson M, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009; 7: 1686-92.
172. Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 2013; 229: 422-9.
173. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-5.
174. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res 2008; 68: 10021-3.
175. Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011; 16: 1397-402.
176. Tong WM, Cortes U, Wang ZQ. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 2001; 1552: 27-37.
177. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28: (suppl; abstr 1019).